<DOC>
	<DOCNO>NCT00281008</DOCNO>
	<brief_summary>The aim study assess safety efficacy vary dos ISIS 301012 ( mipomersen ) add-on therapy subject Heterozygous Familial Hypercholesterolemia</brief_summary>
	<brief_title>Study ISIS 301012 ( Mipomersen ) Heterozygous Familial Hypercholesterolemia Subjects Lipid Lowering Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Mipomersen</mesh_term>
	<criteria>Weight â‰¥ 50 kg Diagnosis Heterozygous Familial Hypercholesterolemia . Females must nonpregnant nonlactating . On stable lipid lower therapy least 4 week . Lipid level meet prespecified criterion . Subject heart problem prior 6 month . Subject elevate ALT , AST , CPK . History renal disease , liver disease , malignancy . Use oral anticoagulant , unless dose stable 4 week Have condition , opinion Investigator would make subject unsuitable enrollment , could interfere subject participate completing study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>LDL-cholesterol</keyword>
	<keyword>apoB-100</keyword>
	<keyword>Heterozygous Familial Hypercholesterolemia</keyword>
</DOC>